A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Status:
Completed

Trial end date:
2016-05-24

Target enrollment:

Participant gender:

An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.

Phase 1

ViiV Healthcare

Covance
GlaxoSmithKline

Fostemsavir